Evogene Ltd.
General ticker "EVGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.3M (TTM average)
Evogene Ltd. follows the US Stock Market performance with the rate: 0.5%.
Estimated limits based on current volatility of 3.1%: low 1.02$, high 1.08$
Factors to consider:
- Total employees count: 192 as of 2013
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.12$, 3.68$]
- 2025-12-31 to 2026-12-31 estimated range: [1.05$, 3.16$]
Financial Metrics affecting the EVGN estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -225.34 <= 0.33
- Positive: Interest expense per share per price, % of 1.42 <= 3.41
- Positive: Return on assets ratio (scaled to [-100,100]) of 31.17 > 6.04
- Positive: Investing cash flow per share per price, % of 110.06 > -0.66
Short-term EVGN quotes
Long-term EVGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.68MM | $5.64MM | $8.51MM |
| Operating Expenses | $28.62MM | $32.03MM | $30.72MM |
| Operating Income | $-26.94MM | $-26.39MM | $-22.21MM |
| Non-Operating Income | $-2.81MM | $0.40MM | $4.17MM |
| Interest Expense | $3.33MM | $0.17MM | $0.12MM |
| R&D Expense | $20.79MM | $18.11MM | $16.65MM |
| Income(Loss) | $-29.75MM | $-25.99MM | $-18.05MM |
| Taxes | $-0.09MM | $0.03MM | $-0.01MM |
| Profit(Loss)* | $-26.64MM | $-23.88MM | $-16.48MM |
| Stockholders Equity | $27.93MM | $12.05MM | $-1.45MM |
| Inventory | $0.57MM | $0.08MM | $1.82MM |
| Assets | $56.13MM | $51.10MM | $39.86MM |
| Operating Cash Flow | $-23.68MM | $-21.58MM | $-19.70MM |
| Capital expenditure | $1.17MM | $0.79MM | $0.63MM |
| Investing Cash Flow | $13.27MM | $-4.54MM | $9.62MM |
| Financing Cash Flow | $9.34MM | $18.15MM | $4.66MM |
| Earnings Per Share** | $-6.46 | $-5.23 | $-2.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.